Evidence map›Paper›PMID 30531947›Full record

ReviewNature reviews. Microbiology2019

Origin and evolution of pathogenic coronaviruses.

Jie Cui, Fang Li, Zheng-Li Shi

5 registry-linked trialsOpen access · hybridAbstract readReview
In one paragraph

Review in Nature reviews. Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 2,791 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,791citing papers in PubMed, 1 pooled it
517.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04362176 phase3completednot on this mapstarted 2020, after this paper: background citation

Passive Immunity Trial for Our Nation (PassItOn)

TypeinterventionalSponsorVanderbilt University Medical CenterRan2020 to 2021Enrolled974ConditionsCOVID-19, Coronavirus, SARS-CoV-2Armspathogen reduced SARS-CoV-2 convalescent plasma, Placebo
NCT04372628 phase2completednot on this mapstarted 2020, after this paper: background citation

Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19

TypeinterventionalSponsorVanderbilt University Medical CenterRan2020 to 2022Enrolled452ConditionsCOVID-19ArmsLopinavir/Ritonavir 400 mg/100 mg, Placebo
NCT04392427 phase3unknown statusnot on this mapstarted 2020, after this paper: background citation

Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: a Pilot Sequential Clinical Trial

TypeinterventionalSponsorMansoura UniversityRan2020 to 2022Enrolled100ConditionsCOVID, Drug EffectArmsTreatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
NCT04420260 nacompletednot on this mapstarted 2021, after this paper: background citation

Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia

TypeinterventionalSponsorUnidad de Investigación Genética MolecularRan2021 to 2021Enrolled152ConditionsCOVIDArmsGroup A: oropharygeal spray and immunostimulant emulsion, Group D:Placebo oropharyngeal spray + Placebo taken PO
NCT05162482 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan: A Randomized Phase II Trial

TypeinterventionalSponsorAga Khan University Hospital, PakistanRan2022 to 2024Enrolled1,680ConditionsCOVID 19 VaccineArmsBIBP (CNBG, Sinopharm) WIV, CanSinoBIO, AstraZeneca ChAdOx
3 · Its place in the literature

Who cites it

2,791 citing papers in PubMed, 1 synthesis or guideline pooled it, 5,807 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

2,731 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Jie CuiCAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.ORCID http://orcid.org/0000-0001-8176-9951
Fang LiDepartment of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN, USA.
Zheng-Li ShiCAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China. zlshi@wh.iov.cn.ORCID http://orcid.org/0000-0001-8089-163X
Chinese Academy of Sciences · CNUniversity of Minnesota · US

Funding

Mechanisms of MERS-CoV Entry, Cross-species Transmission and PathogenesisR01AI110700 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, LI, FANG · 2015 to 2024
$7.4M
Receptor recognition mechanisms of coronavirusesR01AI089728 · NIAID · UNIVERSITY OF MINNESOTA · PI Fang Li, Timothy Patrick Sheahan · 2010 to 2026
$4.7M
Understanding the Risk of Bat Coronavirus EmergenceR01AI110964 · NIAID · ECOHEALTH ALLIANCE, INC. · PI DASZAK, PETER · 2014 to 2023
$4.3M
NIAID NIH HHS R01 AI089728NIAID NIH HHS R01 AI110700NIAID NIH HHS R01 AI110964
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are two highly transmissible and pathogenic viruses that emerged in humans at the beginning of the 21st century. Both viruses likely originated in bats, and genetically diverse coronaviruses that are related to SARS-CoV and MERS-CoV were discovered in bats worldwide. In this Review, we summarize the current knowledge on the origin and evolution of these two pathogenic coronaviruses and discuss their receptor usage; we also highlight the diversity and potential of spillover of bat-borne coronaviruses, as evidenced by the recent spillover of swine acute diarrhoea syndrome coronavirus (SADS-CoV) to pigs.

Indexed as

Genetic VariationGenome, ViralAlphacoronavirusAnimalsChiropteraCoronavirusCoronavirus InfectionsEvolution, MolecularHumansMiddle East Respiratory Syndrome CoronavirusPhylogenySevere Acute Respiratory SyndromeSevere acute respiratory syndrome-related coronavirusSwine

Identifiers

PMID30531947
PMCPMC7097006
OpenAlexW2903899730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.